Showing posts with label drugs. Show all posts
Showing posts with label drugs. Show all posts
in the united states, prescription drugs have become so expensive that at least one insurance company now pays for its members to go to mexico to get their prescriptions filled.
in addition to paying for the trips, the company puts their members up in a hotel overnight and provides a us$500 stipend to cover any other out-of-pocket costs associated with the trip.
in addition to paying for the trips, the company puts their members up in a hotel overnight and provides a us$500 stipend to cover any other out-of-pocket costs associated with the trip.
by 2009, more than half a million american children from adolescence to less than two years of age were taking prescribed antipsychotic medication. despite - or possibly because of - this, the number of patients under 18 receiving federal disability payments for mental illness has multiplied by a factor of 35.
pharmaceutical companies often create and fund front organizations to recommend and endorse their products. for example, the national heart, lung, and blood institute endorses asthma medication advair, which is manufactured by glaxosmithkline... which owns the national heart, lung, and blood institute.
pharmaceutical companies often market the same drug under multiple names in order to broaden market penetration, extend the life of their patents (delaying cheaper generic versions), or to hide negative connotations. for example, sarafem, made by eli lilly, is simply prozac with a name designed to appeal to women.
glaxosmithkline did the same thing with their antidepressant, wellbutrin, which was rebranded as a drug to help you stop smoking, called zyban.
despite the fact that these are clearly different uses, the fda routinely okays 93% of all such repurposing.
glaxosmithkline did the same thing with their antidepressant, wellbutrin, which was rebranded as a drug to help you stop smoking, called zyban.
despite the fact that these are clearly different uses, the fda routinely okays 93% of all such repurposing.
Subscribe to:
Posts (Atom)